proposed 8>1 consolidation, page-20

First 20 Last

Share
Profile

Follow
Investor Bob

4,313 Posts.

539

20/11/21

09:53

Post #: 57719390
Share

Originally posted by asculpeous ↑

WE haven't really discussed why the board is doing this consolidation.
No doubt there's a game a foot that we are not aware off.
Maybe some OS listings are in mind.

Why make the share register tighter?
Maybe they're worried about takeover.

The real juice is the market cap and relationship to peers.
The money should be on a NYSE listing?

Who knows, just guessing as not articulated by the board.How does a consolidation change the business?Will it effect the main driver viz. the uranium bull?None.Games are being played.......as they say if you don't know who the bunny is, it's probably you.

No doubt some financial engineer has been whispering in the board's ear about how it will attract big investors,steady the register etc.
They are probably right although logic tells us otherwise.

Just have to hold strong,watch the space and see what further games are launched on retail to lever the stock into other hands, because we know from the study of cognitive biases that the SP affects shareholder's psyche more than market cap at our end of the market.

For those who use TA,be aware that your indicators may throw off sell signals because the quantum of price move changes suddenly and this makes all technical signals suspect for a year or more before they settle and give more reliable signals.Suspect that this is also the case for chart patterns.

In summary, despite machinations that bear no relationship to the fundamentals of the business, Asculpeous intends to stay long and strong and not let the temptation of apparent big prices make him sell out.

Expand

More often than not the price will drop post consolidation. But that maybe that most company's that do so are "penny dreadfuls".

Boss is not that company. If the price does reverse I will be keen to add to my stash because as you rightly point out nothing has changed.
I am happy to wear the fluffy ears and grow whiskers.

BOE Price at posting: 36.5¢ Sentiment: Buy Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

There are more pages in this discussion • 2 more messages in this thread...

First 20 Last

Add BOE (ASX) to my watchlist

(20min delay)
Last $3.34		Change -0.050(1.47%)		Mkt cap ! $1.368B

Open	High	Low	Value	Volume
$3.43	$3.44	$3.29	$2.243M	666.9K

Buyers (Bids)

No.	Vol.	Price($)
11	5925	$3.33

Sellers (Offers)

Price($)	Vol.	No.
$3.34	9482	10

View Market Depth

No.	Vol.	Price($)
9	9735	3.330
16	33292	3.320
20	60400	3.310
14	57718	3.300
14	28315	3.290

Price($)	Vol.	No.
3.340	15367	10
3.350	49428	14
3.360	41525	9
3.370	20668	7
3.380	150461	5

Last trade - 11.43am 04/10/2024 (20 minute delay)

BOE (ASX) Chart

proposed 8>1 consolidation, page-20

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

proposed 8>1 consolidation, page-20

Top Stories

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News